Trial Profile

A Multicenter, Clinical Trial to Evaluate Crizanlizumab in Children with Sickle Cell Disease (SCD)

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Jun 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Crizanlizumab (Primary)
Indications Sickle cell anaemia
Focus Therapeutic Use

Most Recent Events

24 Jun 2020 New trial record
18 Jun 2020 According to a Novartis media release, the company plans to conduct two clinical trials in Ghana and Kenya for its next-generation treatment for SCD, crizanlizumab.The trials are expected to start in 2020, this will be the first time that a biologic therapy, which is not a vaccine, enters multicenter clinical trials in sub-Saharan Africa (excluding South Africa).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com